|
EP0697214A1
|
|
Liposomal cyclosporin pharmaceutical formulations
|
|
US5328678A
|
|
Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
|
|
US5463092A
|
|
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
|
US5411947A
|
|
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
|
AU3244393A
|
|
Antibiotic formulation and process
|
|
AU668873B2
|
|
Antiviral liponucleosides: treatment of hepatitis B
|
|
WO9218104A1
|
|
Pharmaceutical formulation and process
|
|
US5258499A
|
|
Liposome targeting using receptor specific ligands
|
|
AU1645692A
|
|
Inhibition of aggregation of drug containing particles
|
|
US5320906A
|
|
Delivery vehicles with amphiphile-associated active ingredient
|
|
AU9127991A
|
|
Prevention of synovial adhesions
|
|
US5186941A
|
|
Vesicle formulation for the controlled release of therapeutic agents
|
|
AU8875991A
|
|
Inhibition of viral replication
|
|
AU8876691A
|
|
Phospholipid analogue vesicle with a succinimidyl moiety
|
|
EP0592446A1
|
|
Loading technique for preparing drug containing liposomes
|
|
EP0661044A1
|
|
Drug-containing liposomes
|
|
CA2102235A1
|
|
Method for the administration of drugs
|
|
WO9220323A1
|
|
Methods for the administration of drugs
|
|
WO9106285A1
|
|
Reconstitution method
|
|
US5227170A
|
|
Encapsulation process
|
